Search

Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium.

… Monday, December 1, 2008 Summary Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium. Infection by antibiotic-resistant bacteria is a dangerous complication of broad-spectrum

Computational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award. 

… Tuesday, October 6, 2020 Computational biologist  Thomas Norman, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will

Kravis WiSE promotes gender equity in science by providing stable funding and professional support for women in science at Memorial Sloan Kettering Cancer Center.

… Wednesday, March 6, 2024 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce four  Sloan Kettering Institute  (SKI) researchers have been named 2024  Marie-Josée Kravis WISE  fellowship grant recipients. Kravis WiSE was established in 2020, and is now in its fifth class. Kravis WISE remains

Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.

… Friday, December 2, 2011 Summary Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor. Pictured: Genes & Development Journal

Deb Schrag, MD, MPH, FASCO, gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), has been elected 2027-28 President of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

… Friday, December 19, 2025 Deb Schrag, MD, MPH, FASCO,   gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK),   has been elected 2027-28 President of the  American Society of Clinical Oncology (ASCO ), the world’s leading

Researchers from MSK presented findings on graft-versus-host disease and other topics at the annual meeting of bone marrow transplant and cellular therapy experts.

… Monday, February 26, 2024 Doctors and scientists from Memorial Sloan Kettering Cancer Center (MSK) presented advances in transplantation and cellular therapies at a joint meeting hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and

Our findings indicate that surgical site infections can be reduced effectively over the long term with a hospital-wide implementation of multidisciplinary best practices.

… Thursday, December 13, 2018 Implementation of a multidisciplinary care bundle composed of 13 perioperative components has significantly decreased the rate of surgical site infections (SSIs) among patients undergoing colorectal cancer surgery at Memorial Sloan Kettering Cancer Center, according to our

The Specialized Programs of Research Excellence (SPORE) grant will fund efforts focusing on the development of new treatments.

… Tuesday, September 7, 2021 Memorial Sloan Kettering Cancer Center has received a major grant from the US National Institutes of Health (NIH) to conduct research related to leukemia . It is the sixth grant of this type to be received by MSK investigators. It is referred to as a SPORE grant, for Specialized

Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS, has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK).

… Thursday, July 12, 2018 Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS , has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). An accomplished physician and leader, Dr. Gerstle most recently served as Director of

The immunotherapy drug nivolumab is now approved for patients whose Hodgkin lymphoma has failed other treatments.

… Thursday, May 19, 2016 https://www.youtube.com/watch?v=lrB1gjztQSk The immunotherapy drug nivolumab is giving hope to Hodgkin lymphoma patients like Ariella after standard treatments don’t work. Video courtesy Cancer Research Institute. Summary Patients with Hodgkin lymphoma whose disease returns after